A. Recent history of mild hypoglycemic events B. Current treatment regimen of insulin C. Metformin monotherapy D. Advanced age

A. Temporary loosening of glycemic control B. More frequent blood glucose monitoring C. Switching from a regular or NPH insulin to an insulin analog, metformin, DPP-4 inhibitor, SGLT2-inhibitor, or GLP-1 receptor agonist D. Intensification of the exercise regimen

A. Insulin analogs B. SGLT2-inhibitors C. GLP-1 receptor agonists D. DPP-4 inhibitors E. All of the above

A. Less need for blood glucose monitoring B. Less dose-to-dose variability C. Lower risk of hypoglycemia D. Flatter insulin profiles with less peak effect

A. It represents only a small fraction of hypoglycemic events B. It is linked to dead-in-bed syndrome C. Its symptoms are often asymptomatic, unrecognized, or unreported D. It is signaled by confusion, tiredness upon wakening, and nightmares

A. Less common in older patients than younger patients B. Less stringent A1C goals (<8.0%) may be appropriate C. The use of regular human insulin therapy is preferred D. Lack of awareness is irreversible

A. Exercising before a meal B. Keeping a detailed blood glucose log C. Maintaining regular meal times D. Frequent blood glucose monitoring

A. HAAF is more common in patients with T2DM than T1DM B. HAAF is usually reversible with 2-3 weeks of hypoglycemia avoidance C. HAAF is preceded by hypoglycemia unawareness D. HAAF is associated with an elevated risk of severe hypoglycemia

A. It uses simple yes or no questions B. It engages patients in conversational dialogue that should elicit a behavioral change C. It allows the clinician to reprimand the patient for missed dosing D. It should only be used by the treating physician

A. Inhaled insulin B. Long-acting insulin analogs C. NPH insulin D. Rapid-acting insulin analogs